Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
50%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated1
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

terminated120%
active_not_recruiting120%
completed240%
withdrawn120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_1

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

NCT04004442
completedphase_1

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT03639246
terminatedphase_2

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

NCT04042623
withdrawnphase_1

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

NCT03607955
completedphase_1

A Phase 1 AVB-S6-500 Safety and Tolerability Study

NCT03401528

Clinical Trials (5)

Showing 5 of 5 trials
NCT04004442Phase 1

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active Not Recruiting
NCT03639246Phase 1

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed
NCT04042623Phase 2

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

Terminated
NCT03607955Phase 1

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Withdrawn
NCT03401528Phase 1

A Phase 1 AVB-S6-500 Safety and Tolerability Study

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5